Up
to 99% of systemically administered nanoparticles are cleared
through the liver. Within the liver, most nanoparticles are thought
to be sequestered by macrophages (Kupffer cells), although significant
nanoparticle interactions with other hepatic cells have also been
observed. To achieve effective cell-specific targeting of drugs through
nanoparticle encapsulation, improved mechanistic understanding of
nanoparticle–liver interactions is required. Here, we show
the caudal vein of the embryonic zebrafish (Danio rerio) can be used as a model for assessing nanoparticle interactions
with mammalian liver sinusoidal (or scavenger) endothelial cells (SECs)
and macrophages. We observe that anionic nanoparticles are primarily
taken up by SECs and identify an essential requirement for the scavenger
receptor, stabilin-2 (stab2) in
this process. Importantly, nanoparticle–SEC interactions can
be blocked by dextran sulfate, a competitive inhibitor of stab2 and other scavenger receptors. Finally, we exploit
nanoparticle–SEC interactions to demonstrate targeted intracellular
drug delivery resulting in the selective deletion of a single blood
vessel in the zebrafish embryo. Together, we propose stab2 inhibition or targeting as a general approach for modifying nanoparticle–liver
interactions of a wide range of nanomedicines.